The American Association for Cancer Research annual meeting wrapped up today in Chicago. Below are selected business briefs from the conference.
The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.
Areas of concern are the recruitment of talented scientists, as well as retaining access to EU funding, European research collaborations, and clinical trials.
A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.
The two studies came out of the UK's Tracking Cancer Evolution through Therapy (TRACERx) trial.
Speakers at the conference's opening plenary showed how their work in cancer research fit into the broad theme of 'Discover, Predict, Prevent, Treat.'
The new funding supports clinical trials as well as preclinical work to identify biomarkers of therapeutic response.
The researchers will sequence the genomes and transcriptomes of 250 breast cancer patients in the first phase, returning information from 16 actionable genes.
Inivata plans to use the new funds to accelerate clinical studies to validate its liquid biopsy technology platform and commercialize its first products.
The work identified specific groups of somatic mutations that might be ideal to hunt for in ctDNA to monitor tumor burden, guide treatment, or follow therapeutic response.
The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.
Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.
The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.
In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.